Featured Review: MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression
The p38 mitogen-activated protein kinase (p38MAPK) pathway has been implicated in a variety of pathological conditions including inflammation and metastasis. Post-transcriptional regulation of genes harboring adenine/uridine-rich elements (AREs) in their 3′-untranslated region (3′-UTR) is controlled by MAPK-activated protein kinase 2 (MAPKAPK2 or MK2), a downstream substrate of the p38MAPK. In response to diverse extracellular stimuli, MK2 influences crucial signaling events, regulates inflammatory cytokines, transcript stability and critical cellular processes. Expression of genes involved in these vital cellular cascades is controlled by subtle interactions in underlying molecular networks and post-transcriptional gene regulation that determines transcript fate in association with RNA-binding proteins (RBPs). Several RBPs associate with the 3′-UTRs of the target transcripts and regulate their expression via modulation of transcript stability. Although MK2 regulates important cellular phenomenon, yet its biological significance in tumor progression has not been well elucidated till date. In this review, Padwad et al have highlighted in detail the importance of MK2 as the master regulator of RBPs and its role in the regulation of transcript stability, tumor progression, as well as the possibility of use of MK2 as a therapeutic target in tumor management.
Reviews from Journal of Experimental & Clinical Cancer Research
Page 1 of 4
Drug repurposing against COVID-19: focus on anticancer agents
The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III tri...39:86Journal of Experimental & Clinical Cancer Research 2020Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma
The majority of high-risk neuroblastomas can be divided into three distinct molecular subgroups defined by the presence of MYCN amplification, upstream TERT rearrangements or alternative lengthening of telomeres ...39:78Journal of Experimental & Clinical Cancer Research 2020Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional in vitro models
The heterogeneous tumor microenvironment (TME) is highly complex and not entirely understood. These complex configurations lead to the generation of oxygen-deprived conditions within the tumor niche, which mod...39:75Journal of Experimental & Clinical Cancer Research 2020Exosomal miRNAs in tumor microenvironment
Tumor microenvironment (TME) is the internal environment in which tumor cells survive, consisting of tumor cells, fibroblasts, endothelial cells, and immune cells, as well as non-cellular components, such as e...39:67Journal of Experimental & Clinical Cancer Research 2020Dissecting the transcriptional regulatory networks of promoter-associated noncoding RNAs in development and cancer
In-depth analysis of global RNA sequencing has enabled a comprehensive overview of cellular transcriptomes and revealed the pervasive transcription of divergent RNAs from promoter regions across eukaryotic gen...39:51Journal of Experimental & Clinical Cancer Research 2020Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers
The promising expectations about personalized medicine have opened the path to routine large-scale sequencing and increased the importance of genetic counseling for hereditary cancers, among which hereditary b...39:46Journal of Experimental & Clinical Cancer Research 2020The interplay between HIF-1α and noncoding RNAs in cancer
Hypoxia is a classic characteristic of the tumor microenvironment with a significant impact on cancer progression and therapeutic response. Hypoxia-inducible factor-1 alpha (HIF-1α), the most important transcr...39:27Journal of Experimental & Clinical Cancer Research 2020Vitamin D, gut microbiota, and radiation-related resistance: a love-hate triangle
Radiation resistance is a serious issue in radiotherapy. Increasing evidence indicates that the human gut microbiome plays a role in the development of radiation resistance. Vitamin D is an important supplemen...38:493Journal of Experimental & Clinical Cancer Research 2019Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects
Growing evidence showed the increased prevalence of cancer incidents, particularly colorectal cancer, among type 2 diabetic mellitus patients. Antidiabetic medications such as, insulin, sulfonylureas, dipeptyl...38:491Journal of Experimental & Clinical Cancer Research 2019Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian...38:447Journal of Experimental & Clinical Cancer Research 2019Recent advances in nanotheranostics for triple negative breast cancer treatment
Triple-negative breast cancer (TNBC) is the most complex and aggressive type of breast cancer encountered world widely in women. Absence of hormonal receptors on breast cancer cells necessitates the chemothera...38:430Journal of Experimental & Clinical Cancer Research 2019Activity of MCPIP1 RNase in tumor associated processes
The monocyte chemoattractant protein-induced protein (MCPIP) family consists of 4 members (MCPIP1–4) encoded by the ZC3h12A-D genes, which are located at different loci. The common features of MCPIP proteins are ...38:421Journal of Experimental & Clinical Cancer Research 2019Immunotherapy of brain metastases: breaking a “dogma”
Until very few years ago, the oncology community dogmatically excluded any clinical potential for immunotherapy in controlling brain metastases. Therefore, despite the significant therapeutic efficacy of monoc...38:419Journal of Experimental & Clinical Cancer Research 2019Iron and leukemia: new insights for future treatments
Iron, an indispensable element for life, is involved in all kinds of important physiological activities. Iron promotes cell growth and proliferation, but it also causes oxidative stress damage. The body has a ...38:406Journal of Experimental & Clinical Cancer Research 2019Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy
T cells play important roles in anti-tumor immunity. Emerging evidence has revealed that distinct metabolic changes impact the activation and differentiation of T cells. Tailoring immune responses by manipulat...38:403Journal of Experimental & Clinical Cancer Research 2019From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in HCC treatment, less than 40% o...38:396Journal of Experimental & Clinical Cancer Research 2019Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of surv...38:368Journal of Experimental & Clinical Cancer Research 2019RhoC: a fascinating journey from a cytoskeletal organizer to a Cancer stem cell therapeutic target
Tumor heterogeneity results in differential response to therapy due to the existence of plastic tumor cells, called cancer stem cells (CSCs), which exhibit the property of resistance to therapy, invasion and m...38:328Journal of Experimental & Clinical Cancer Research 2019Effects of hyperglycemia on the progression of tumor diseases
Malignant tumors are often multifactorial. Epidemiological studies have shown that hyperglycemia raises the prevalence and mortality of certain malignancies, like breast, liver, bladder, pancreatic, colorectal...38:327Journal of Experimental & Clinical Cancer Research 2019Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway
Numerous studies have presented that curcumin could have a positive effect in the prevention of cancer and then in tumor therapy. Several hypotheses have highlighted that curcumin could decreases tumor growth ...38:323Journal of Experimental & Clinical Cancer Research 2019Role of protein kinase CK2 in antitumor drug resistance
Drug resistance represents the major reason of pharmacological treatment failure. It is supported by a broad spectrum of mechanisms, whose molecular bases have been frequently correlated to aberrant protein ph...38:287Journal of Experimental & Clinical Cancer Research 2019MET in glioma: signaling pathways and targeted therapies
Gliomas represent the most common type of malignant brain tumor, among which, glioblastoma remains a clinical challenge with limited treatment options and dismal prognosis. It has been shown that the dysregula...38:270Journal of Experimental & Clinical Cancer Research 2019Advances in cancer immunotherapy 2019 – latest trends
Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. The two main drivers behind this succes...38:268Journal of Experimental & Clinical Cancer Research 2019Autophagy manipulation as a strategy for efficient anticancer therapies: possible consequences
Autophagy is a catabolic process whose activation may help cancer cells to adapt to cellular stress although, in some instances, it can induce cell death. Autophagy stimulation or inhibition has been considere...38:262Journal of Experimental & Clinical Cancer Research 2019Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and p...38:255Journal of Experimental & Clinical Cancer Research 2019The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review
FAK is a tyrosine kinase overexpressed in cancer cells and plays an important role in the progression of tumors to a malignant phenotype. Except for its typical role as a cytoplasmic kinase downstream of integ...38:250Journal of Experimental & Clinical Cancer Research 2019MicroRNA based theranostics for brain cancer: basic principles
Because of the complexity of the blood-brain barrier (BBB), brain tumors, especially the most common and aggressive primary malignant tumor type arising from the central nervous system (CNS), glioblastoma, rem...38:231Journal of Experimental & Clinical Cancer Research 2019FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors – implications for therapy of luminal breast cancer
Stromal stimuli mediated by growth factor receptors, leading to ligand-independent activation of steroid hormone receptors, have long been implicated in development of breast cancer resistance to endocrine the...38:230Journal of Experimental & Clinical Cancer Research 2019The roles of glucose metabolic reprogramming in chemo- and radio-resistance
Reprogramming of cancer metabolism is a newly recognized hallmark of malignancy. The aberrant glucose metabolism is associated with dramatically increased bioenergetics, biosynthetic, and redox demands, which ...38:218Journal of Experimental & Clinical Cancer Research 2019Effects of short-term fasting on cancer treatment
Growing preclinical evidence shows that short-term fasting (STF) protects from toxicity while enhancing the efficacy of a variety of chemotherapeutic agents in the treatment of various tumour types. STF reinfo...38:209Journal of Experimental & Clinical Cancer Research 2019Molecular pattern of lncRNAs in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most notable lethal malignancies worldwide. However, the molecular mechanisms involved in the initiation and progression of this disease remain poorly understood. O...38:198Journal of Experimental & Clinical Cancer Research 2019STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Triple negative breast cancer (TNBC), which is typically lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), represents the most aggre...38:195Journal of Experimental & Clinical Cancer Research 2019The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer
Cancer-associated fibroblasts (CAFs) plays an essential role in cancer cell growth, metabolism and immunoreaction. Autophagy is an intracellular self-degradative process that balances cell energy source and re...38:171Journal of Experimental & Clinical Cancer Research 2019Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
Pancreatic cancer is one of the most lethal type of cancers, with an overall five-year survival rate of less than 5%. It is usually diagnosed at an advanced stage with limited therapeutic options. To date, no ...38:162Journal of Experimental & Clinical Cancer Research 2019Clinical development of targeted and immune based anti-cancer therapies
Cancer is currently the second leading cause of death globally and is expected to be responsible for approximately 9.6 million deaths in 2018. With an unprecedented understanding of the molecular pathways that...38:156Journal of Experimental & Clinical Cancer Research 2019Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
The recent developments in immuno-oncology have opened an unprecedented avenue for the emergence of vaccine strategies. Therapeutic DNA cancer vaccines are now considered a very promising strategy to activate ...38:146Journal of Experimental & Clinical Cancer Research 20193D models in the new era of immune oncology: focus on T cells, CAF and ECM
Immune checkpoint inhibitor therapy has changed clinical practice for patients with different cancers, since these agents have demonstrated a significant improvement of overall survival and are effective in ma...38:117Journal of Experimental & Clinical Cancer Research 2019MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression
The p38 mitogen-activated protein kinase (p38MAPK) pathway has been implicated in a variety of pathological conditions including inflammation and metastasis. Post-transcriptional regulation of genes harboring ...38:121Journal of Experimental & Clinical Cancer Research 2019Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology
The extracellular matrix (ECM) plays an important role in cancer progression. It can be divided into the basement membrane (BM) that supports epithelial/endothelial cell behavior and the interstitial matrix (I...38:115Journal of Experimental & Clinical Cancer Research 2019New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
Novel therapeutic strategies are urgently needed for the treatment of metastatic Urothelial Bladder Cancer. DNA damaging repair (DDR) targeting has been introduced in cinical trials for bladder cancer patients...38:91Journal of Experimental & Clinical Cancer Research 2019Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
PD-1/PD-L1 checkpoint blockades have achieved significant progress in several kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung c...38:87Journal of Experimental & Clinical Cancer Research 2019MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
MicroRNA-34 (miR-34) has been reported to be dysregulated in various human cancers and regarded as a tumor suppressive microRNA because of its synergistic effect with the well-known tumor suppressor p53. Along...38:53Journal of Experimental & Clinical Cancer Research 2019Emerging roles of telomeric chromatin alterations in cancer
Telomeres, the nucleoprotein structures that cap the ends of eukaryotic chromosomes, play important and multiple roles in tumorigenesis. Functional telomeres need the establishment of a protective chromatin st...38:21Journal of Experimental & Clinical Cancer Research 2019RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
RANKL/RANK/OPG system consists of three essential signaling molecules: i) the receptor activator of nuclear factor (NF)-kB-ligand (RANKL), ii) the receptor activator of NF-kB (RANK), and iii) the soluble decoy...38:12Journal of Experimental & Clinical Cancer Research 2019Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting
Pancreatic cancer (PC) is among foremost causes of cancer related deaths worldwide due to generic symptoms, lack of effective screening strategies and resistance to chemo- and radiotherapies. The risk factors ...37:319Journal of Experimental & Clinical Cancer Research 2018Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia
Resistance to regulated cell death is one of the hallmarks of human cancers; it maintains cell survival and significantly limits the effectiveness of conventional drug therapy. Leukemia represents a class of h...37:310Journal of Experimental & Clinical Cancer Research 2018Correction to: Emerging roles of Myc in stem cell biology and novel tumor therapies
In the publication of this article [1] there are three errors.37:285Journal of Experimental & Clinical Cancer Research 2018The role of cellular reactive oxygen species in cancer chemotherapy
Most chemotherapeutics elevate intracellular levels of reactive oxygen species (ROS), and many can alter redox-homeostasis of cancer cells. It is widely accepted that the anticancer effect of these chemotherap...37:266Journal of Experimental & Clinical Cancer Research 2018Recent advances in searching c-Myc transcriptional cofactors during tumorigenesis
The mechanism by which c-Myc exerts its oncogenic functions is not completely clear and different hypotheses are still under investigation. The knowledge of the capacity of c-Myc to bind exclusively E-box sequ...37:239Journal of Experimental & Clinical Cancer Research 2018The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, and it is one of the leading causes of cancer death in both men and women worldwide due to diagnosis in the advanced stag...37:226Journal of Experimental & Clinical Cancer Research 2018
No hay comentarios:
Publicar un comentario